Privatizing biomedical research - a 'third way'

被引：13

作者：

Bouchard, Ron A. ^{[1
]}

Lemmens, Trudo ^{[2
]}

机构：

[1] Univ Alberta, Fac Law & Med & Dent, Edmonton, AB T6G 2H5, Canada

[2] Univ Toronto, Fac Law & Med, Toronto, ON M5S 2C5, Canada

来源：

NATURE BIOTECHNOLOGY | 2008年 / 26卷 / 01期

关键词：

D O I：

10.1038/nbt0108-31

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The allocation of risks and benefits of publicly sponsored biomedical research is becoming increasingly skewed toward for-profit entities and against the public interest. A legitimate solution to this imbalance would be to levy compulsory government royalty fees on commercial products made possible by public efforts.

引用

页码：31 / 36

页数：6

共 55 条

[41] Looking for solid ground along the Critical Path [J].

Ratner, Mark .

NATURE BIOTECHNOLOGY, 2006, 24 (08) :885-887

[42]

Ravetz Jerome R., 1971, Scientific Knowledge and Its Social Problems

[43] AMERICAN UNIVERSITIES AND TECHNICAL ADVANCE IN INDUSTRY [J].

ROSENBERG, N ;

NELSON, RR .

RESEARCH POLICY, 1994, 23 (03) :323-348

[44] Patenting and US academic research in the 20th century: The world before and after Bayh-Dole [J].

Sampat, Bhaven N. .

RESEARCH POLICY, 2006, 35 (06) :772-789

[45] Clinical trial registration:: transparency is the watchword [J].

Sim, I ;

Chan, AW ;

Gülmezoglu, AM ;

Evans, T ;

Pang, T .

LANCET, 2006, 367 (9523) :1631-1633

[46]

Stolberg S G, 2000, N Y Times Web, pA15

[47]

United Nations, 1976, INT CONV EC SOC CULT

[48]

*US C, 1993, PHARM R D COSTS RISK

[49]

*US FDA, 2007, CRIT PATH WHIT PAP I

[50]

*US NIH, 2001, NIH RESP C REP REQ P

← 1 2 3 4 5 6 →